In the long 4-year study of efficacy and safety of Proscar on 3016 patients with moderate to severe symptoms of benign prostatic hyperplasia has been evaluated the effect of drug treatment for urological intervention (surgical manipulations or catheterization for acute urinary retention) caused by the disease of BPH. In this double-blind, randomized, placebo-controlled multicenter study treatment with Proscar reduced the risk of urologic interventions by 51% and was accompanied by a marked and persistent decrease in prostate volume, and the persistent increase in the maximum rate of urine flow and improving symptoms.
Proscar is indicated for the treatment and control of benign prostatic hyperplasia and urological interventions to:
- reduce the risk of acute urinary retention;
- reduce the risk of surgical procedures, including transurethral resection of the prostate and prostatectomy.
Proscar decreases the size of enlarged prostate, improves urine flow and reduces the symptoms associated with BPH.
The present long-term open-label study of patients with BPH confirmed that Proscar, applied in 160mg 2 times a day for 2 years, shows a good clinical effect and biologically safe. Confirmed its effectiveness to alleviate LUTS due to BPH. The study showed that the drug continued to reduce the severity of symptoms within 2 years of observation. Demonstrated a 14% reduction in prostate volume after treatment with Proscar. It is established that the drug does not affect the plasma concentration of PSA, androgen levels, significantly improves sexual function and quality of life.
Thus, Proscar (Finasteride) therapy in patients with uncomplicated benign prostatic hyperplasia is an alternative method of treatment, which should be conducted during a long period of time.